TOPIC: One Lot of Thyroid Tablets USP, 30 mg by Vitruvias Therapeutics: Recall - Due to Potential Super Potency
AUDIENCE: Patient, Health Care Professional, Pharmacy, Endocrinology, Cardiology
ISSUE: Vitruvias Therapeutics is recalling one lot (Lot. No. 504950) of Thyroid Tablets, USP 30 mg because testing confirmed the potential for the product to be superpotent.
Risk Statement: Consumption of superpotent Thyroid tablets can cause hyperthyroidism (overactive thyroid) including, but not limited to, weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate, or heart rhythm disturbances. The patient population at greater risk from superpotent thyroid are elderly, pregnant women, and infants, especially over extended periods of time. Excess levels of thyroid hormones in the elderly have been associated with adverse outcomes, particularly to cardiac health. Overtreatment of hypothyroidism in pregnancy is associated with a higher rate of maternal and fetal complications, including premature delivery and low birth weight. Overtreatment of hypothyroidism in infants may have negative effects on growth and development.
Lot 504950 was distributed nationwide in the USA to Vitruvias Therapeutics' direct accounts from Jan. 31, 2025 to Sept. 30, 2025.
To date, Vitruvias Therapeutics has not received any reports of adverse events known to be related to this recall.
For more information about this recall, click on the red button "Read Recall" below.
BACKGROUND: Thyroid, USP is a natural preparation derived from porcine thyroid glands composed of levothyroxine and liothyronine and used to treat hypothyroidism (underactive thyroid).
RECOMMENDATIONS:
-
Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
-
Consumers with questions about the recall can contact Vitruvias Therapeutics, Inc. by email at safety@vitruvias.com or by phone at (256) 239-9373.
-
Patients who are currently taking Thyroid, USP from Lot 504950, which is being recalled, should not discontinue use without contacting their healthcare provider for further guidance and/or a replacement prescription.
|
